Abstract

Introduction Anticitrullinated peptide antibody (ACPA) responses for 22 citrullinated peptides in patients with early rheumatoid arthritis (RA) were analysed and related to radiological and clinical outcome during the first 2 years in a prospective inception cohort.

Methods The ACPA reactivities were assessed in 1022 patients with early RA (symptoms <12 months) using the custom-made microarray chip (Thermo Fisher Scientific, Uppsala, Sweden) in a prospective longitudinal study of observational assessments of Disease Activity Score (DAS28 and its components) and radiology during the first 24 months, accounting for the treatment.

Conclusions Several ACPA reactivities modified significantly the DAS28 development during the first 24 months and were significantly associated with Larsen score at baseline, 24 months and radiological progression.

Early rheumatoid arthritis

anti-citrullinated protein/peptide antibodies (ACPA)

multiplex antibody analyses

Larsen score

28-joint disease activity score (DAS28)

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Footnotes

Contributors AB, JR, LK and SR-D made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; MH, LM-A and EB have been involved in analysing the data of the samples and of the patients. All authors have been involved in drafting the manuscript or revising it critically for important intellectual content; AB, MB, AL and SR-D have been involved in analysing and calculating the data; RH, KS and GS have provided the antigens of the peptides. All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Funding This study was supported by grants from the Swedish Research Council (K2013-52X-2030707-3 and Dnr:2018-02551), King Gustaf V’s 80-Year Fund, King Gustaf V’s and Queen Victoria’s Fund, the Swedish Rheumatism Association, Umeå University, Umeå, Sweden.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The patients gave their written informed consent and the Regional Ethics Committee at Umeå University Hospital approved the study.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.